Hidden Lake Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Hidden Lake Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-152,448	Closed	-$3.07M	–	52
2025 Q4	$3.07M	Sell	152,448 -161,588	-51%	-$3.36M	0.78%	24
2025 Q3	$5.79M	Sell	314,036 -292,815	-48%	-$5.75M	0.74%	25
2025 Q2	$13.2M	Buy	606,851 +352,480	+139%	+$7.32M	3.6%	9
2025 Q1	$4.7M	Buy	254,371 +69,766	+38%	+$1.71M	3.04%	12
2024 Q4	$4.92M	Buy	+184,605	New	+$5.3M	2.21%	19
2024 Q3	–	Sell	-37,121	Closed	-$689K	–	48
2024 Q2	$689K	Buy	+37,121	New	+$662K	0.53%	26

Other funds holding AVBP

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Hidden Lake Asset Management's AVBP Position: Q1 2026 in Review

Hidden Lake Asset Management sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 152,448 shares — an estimated $3.07M sold.

Hidden Lake Asset Management first reported a position in AVBP in Q2 2024 and held it in 6 quarters. The position peaked at $13.2M in Q2 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

Hidden Lake Asset Management reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
Hidden Lake Asset Management sold 152,448 ArriVent BioPharma shares in Q1 2026, an estimated $3.07M.
Hidden Lake Asset Management first reported a position in ArriVent BioPharma in Q2 2024 and held it in 6 quarters.
Hidden Lake Asset Management's ArriVent BioPharma position peaked at $13.2M in Q2 2025.
139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Hidden Lake Asset Management's 13F filing for Q1 2026, filed 14 May 2026.